Investigating the anti-cataract potential of Spirulina platensis: Metabolite screening and molecular docking studies
DOI:
https://doi.org/10.12923/cipms-2025-0011Keywords:
Spirulina platensis, HR-LCMS, molecular docking, anti-cataract activity, biochemical parametersAbstract
Diabetes is a chronic metabolic condition that can lead to various complications, including cataracts, a chief cause of visual impairment. There is growing promise in the use of natural compounds as preventive and therapeutic agents for cataracts. Oxidative stress has been implicated as a significant factor in cataract development. Natural compounds with antioxidant properties show potential in combating oxidative stress and preventing the formation of cataracts. Among these compounds, Spirulina platensis has been chosen for investigation in this study due to its well-established antioxidant properties. Additionally, this study aims to explore Spirulina platensis as a potential inhibitor of human aldose reductase (hAR), which is proven to show a fundamental role in cataract development. In the course of the work, Spirulina platensis underwent Soxhlet extraction with methanol, yielding four-column fractions (eluotropic solvent series). Each extract was subjected to HR-LCMS metabolite screening. Molecular docking studies were conducted to identify potential hAR inhibitors, and in vitro, anti-cataract activity was assessed using a goat lens model. The methanol fraction (500 μg/ml) showed the most significant anti-cataract activity, with a lens morphology grade 1 and improvements in superoxide dismutase (SOD) activity (1.565±0.10 U/mg of tissue, p<0.001), catalase (CAT) levels (6.59±0.25 U/mg of tissue, p<0.001), glutathione (GSH) concentrations (21.19±21.19 nmoles/100 mg, p<0.001) and protein content (255.5±5 mg/dl, p<0.001). Molecular docking identified Dubamine (methanol fraction, docking score: -11.0 kcal/mol) as a potential hAR inhibitor with the highest binding affinity. These results demonstrate the molecular pathways underlying Spirulina platensis therapeutic potential against cataracts.
References
1. Mrugacz M, Pony-Uram M, Bryl A, Zorena K. Current approach to the pathogenesis of diabetic cataracts. Int J Mol Sci. 2023;24(7):6317.
2. Muchuchuti S, Viriri S. Retinal disease detection using deep learning techniques: A comprehensive review. J Imaging. 2023;9(4):84.
3. Zhang Z, Wang Y, Zhang H, Samusak A, Rao H, Xiao C, et al. Artificial intelligence-assisted diagnosis of ocular surface diseases. Front Cell Develop Biol. 2023;11:165.
4. Shu DY, Chaudhary S, Cho KS, Lennikov A, Miller WP, Thorn DC, et al. Role of Oxidative stress in ocular diseases: a balancing act. Metabolites. 2023;13(2):187.
5. Rodella U, Honisch C, Gatto C, Ruzza P, D’Amato Tóthová J. Antioxidant nutraceutical strategies in the prevention of oxidative stress related eye diseases. Nutrients. 2023;15(10):2283.
6. Tao JX, Zhou WC, Zhu XG. Mitochondria as potential targets and initiators of the blue light hazard to the retina. Oxid Med Cell Longev. 2019;2019.
7. Liton PB, Boesze-Battaglia K, Boulton ME, Boya P, Ferguson TA, Ganley IG, et al. Autophagy in the eye: from physiology to pathophysiology. Autophagy Rep. 2023;2(1):2178996.
8. Ashwin PT, Shah S, Wolffsohn JS. Advances in cataract surgery. Clin Exp Optom. 2009;92(4):333-42.
9. Chen X, Xu J, Chen X, Yao K. Cataract: Advances in surgery and whether surgery remains the only treatment in future. AOPR. 2021;1(1):100008.
10. Katiyar R, Banerjee S, Arora A. Recent advances in the integrated biorefinery concept for the valorization of algal biomass through sustainable routes. Biofpr. 2021;15(3):879-98.
11. AlFadhly NK, Alhelfi N, Altemimi AB, Verma DK, Cacciola F, Narayanankutty A. Trends and technological advancements in the possible food applications of Spirulina and their health benefits: A Review. Molecules. 2022;27(17):5584.
12. Bhagea R, Hossen AM, Ruhee D, Puchooa D, Bhoyroo V, Boodia N. Microalgae as sources of green bioactives for health-enhancing food supplements and nutraceuticals: A review of literature. Am J Biopharm Pharm Sci. 2022;2.
13. Rajauria G, Yuan YV. Algae: A functional food with a rich history and future superfood. Recent Advances in Micro and Macroalgal Processing: Food and Health Perspectives; 2021:1-3.
14. Dhamak VM, Amrutkar SV. Nephroprotective Effects of Spirulina platensis on NRK-52E cell line: LC-HRMS and docking studies targeting epidermal growth factor receptor. Trop J Nat Prod Res. 2023;7(7).
15. Fais G, Manca A, Bolognesi F, Borselli M, Concas A, Busutti M, Broggi G, et al. Wide range applications of Spirulina: from earth to space missions. Marine Drugs. 2022;20(5):299
16. Pinto LF, Ferreira GF, Beatriz FP, Cabral FA, Maciel Filho R. Lipid and phycocyanin extractions from Spirulina and economic assessment. J Supercrit Fluids. 2022;184:105567.
17. Agustini NW, Wijayanto Y. Isolation, identification of fatty acids from Spirulina platensis as antibacterial. In: IOP Conference Series: Earth and Environmental Science 2020;457(1):012033.
18. Saefurahman G, Rahman AA, Hidayatuloh S, Farobie O, Abidin Z. Continuous extraction of Spirulina platensis pigments using different extraction sequences. In: IOP Conference Series: Earth and Environmental Science. 2021;749(1):012005.
19. Sana TR, Roark JC, Li X, Waddell K, Fischer SM. Molecular formula and METLIN Personal Metabolite Database matching applied to the identification of compounds generated by LC/TOF-MS. JBT. 2008;19(4):258.
20. Tautenhahn R, Cho K, Uritboonthai W, Zhu Z, Patti GJ, Siuzdak G. An accelerated workflow for untargeted metabolomics using the METLIN database. Nature Biotechnol. 2012;30(9):826-8.
21. Guijas C, Montenegro-Burke JR, Domingo-Almenara X, Palermo A, Warth B, Hermann G, et al. METLIN: a technology platform for identifying knowns and unknowns. Anal Chem. 2018;90(5):3156-64.
22. Kador PF, Wyman M, Oates PJ. Aldose reductase, ocular diabetic complications and the development of topical Kinostat®. Prog Retin Eye Res. 2016;54:1-29.
23. Petrash J, Huang SP. Elevation of aldose reductase in the diabetic eye. IOVS. 2007;48(13):2029.
24. Jannapureddy S, Sharma M, Yepuri G, Schmidt AM, Ramasamy R. Aldose reductase: an emerging target for development of interventions for diabetic cardiovascular complications. Front Endocrinol. 2021;12:636267.
25. Maanvizhi S, Narayanaswamy R, Wai LK, Gnanamani A. Molecular docking analysis of embelin and its metal complexes as human aldose reductase (HAR) inhibitor. Pharm Lett. 2014;6:165-8.
26. Khan MS, Qais FA, Rehman MT, Ismail MH, Alokail MS, Altwaijry N, et al. Mechanistic inhibition of non-enzymatic glycation and aldose reductase activity by naringenin: Binding, enzyme kinetics and molecular docking analysis. Int J Biol Macromol. 2020;159:87-97.
27. Haroon HB, Perumalsamy V, Nair G, Anand DK, Kolli R, Monichen J, et al. Repression of polyol pathway activity by Hemidesmus indicus var. pubescens R. Br. Linn root extract, an aldose reductase inhibitor: an in silico and ex vivo study. Nat Prod Bioprospect. 2021;11:315-24.
28. Kumar M, Singh T, Ali J, Tyagi LK. In vitro anticataract activity of Zingiber officinale on goat lenses. Int J Pharm Biol Arch. 2011;2:1430-3.
29. Hajarnavis AM, Bulakh PM. Anticataract effects of S. cumini and A. marmelos on goat lenses in an experimental diabetic cataract model. J Ayurveda Integr Med. 2020;11(4):421-5.
30. Nimbalkar VV, Pansare PM, Nawale DS, Nishane BB. Investigation of carvedilol as an antidenaturing and anticataract agent. Res J Pharm Tech. 2015;8(5):511-6.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
